Related Experiment Video
Updated: Apr 6, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
10.6K
Association of CYP2J2 gene polymorphisms with ischemic stroke
Qing Li1, Jian-Hua Zhao1, Peng-Ju Ma2
1Department of Neurology, First Affiliated Hospital of Xinxiang Medical University Weihui 453100, Henan, P. R. China.
Summary
Genetic variations in the CYP2J2 gene, specifically the G-50T polymorphism, are linked to an increased risk of ischemic stroke (IS) in the Chinese Han population. This finding highlights a potential genetic predisposition to stroke.
Area of Science:
- Genetics
- Cardiovascular Science
- Epidemiology
Background:
- Ischemic stroke (IS) is a significant health concern globally.
- Genetic factors play a role in the susceptibility to IS.
- The Cytochrome P450 family, specifically CYP2J2, is implicated in various physiological processes.
Purpose of the Study:
- To investigate the association between CYP2J2 gene polymorphisms and the risk of ischemic stroke.
- To analyze the G-50T polymorphism in the CYP2J2 gene within a Chinese Han population.
Main Methods:
- A case-control study design was employed.
- 300 patients with ischemic stroke and 300 healthy controls were recruited.
- Genotyping for the CYP2J2 G-50T polymorphism was performed and compared between groups.
Main Results:
- The GT genotype of the CYP2J2 G-50T polymorphism was found more frequently in IS patients (13.7%) compared to controls (7.7%).
- This association remained statistically significant after adjusting for potential confounding factors (OR = 1.890, 95% CI: 1.042-3.011).
Conclusions:
- CYP2J2 gene polymorphism, specifically the G-50T variant, may contribute to an increased risk of ischemic stroke.
- These findings suggest a potential genetic marker for stroke risk in the studied population.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
199
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
199
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
114
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
114
01:27Pharmacogenetics of Drug Metabolism: Overview
125
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
125
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
131
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
131
01:27Principles of Pharmacogenetics: Types of Genetic Variants
98
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
98